Health & Fitness
Health and Fitness
Health and Fitness 
Mon, April 18, 2011
Anacor Pharmaceuticals to Present New Data on AN2728 and GSK a052 at Upcoming Meetings
PALO ALTO, Calif.--([ BUSINESS WIRE ])--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it will present data on two of its compounds at the following conferences:
"Interspecies scaling for prediction of human intravenous pharmacokinetics of GSK2251052 (GSK a052), a novel boron-based antimicrobial against Gram-negative bacteria"
- 2011 Society for Investigative Dermatology (SID) Annual Meeting
- Lee Zane, M.D., Anacora™s Chief Medical Officer, will present aSafety and efficacy of AN2728 ointment in a phase 2b dose-ranging bilateral study of mild-to-moderate plaque psoriasisa in a poster session on Thursday May 5, 2011 at 10 a.m. MT / 9 a.m. PT.
- 21st European Congress of Clinical Microbiology and Infectious Diseases
- Liang Liu, Senior Director of Pharmacokinetics and Drug Metabolism, will present aInterspecies scaling for prediction of human intravenous pharmacokinetics of GSK2251052 (GSK a052), a novel boron-based antimicrobial against Gram-negative bacteriaa in poster topic 17 onSaturday May 7, 2011 at 3:30 p.m. CET / 6:30 a.m. PT.
- Dr. Zane will present aSafety, tolerability, and pharmacokinetics of a novel Gram-negative antimicrobial, GSK2251052 (GSK a052), in healthy subjectsa in poster topic 65 on Monday May 9, 2011 at 12:30 p.m. CET / 3:30 a.m. PT.
Posters from the presentations will be available at the time of each session on Anacora™s website at [ www.anacor.com ].
About AN2728
AN2728 is a topical anti-inflammatory product candidate for the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the United States and over 100 million people worldwide. AN2728 is a boron-based small-molecule compound which inhibits the activity of phosphodiesterase-4 (PDE4), thereby reducing the production of TNF-alpha, IL-12, IL-23 and other pro-inflammatory cytokines that are the precursors of the inflammation associated with psoriasis. AN2728 is currently in its final Phase 2b study, a double-blind, randomized, vehicle-controlled trial with data expected in mid-2011.
About GSK a052
GSKa052 is a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria. Gram-negative bacterial infections are increasing in prevalence, especially in hospitals, and represent a serious public health challenge due to their growing resistance to currently available drug therapies. Gram-negative bacteria are responsible for more than 30.0% of hospital-acquired infections and account for approximately 70.0% of hospital-acquired infections in the intensive care unit. Following the completion of the Phase1 trial, GSK exercised its option to obtain an exclusive license to develop and commercialize GSKa052 and has assumed responsibility for further development of the product candidate and any resulting commercialization.
AboutAnacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered five clinical compounds that are currently in development, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK a052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed toGlaxoSmithKlineunder the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. For more information visit[ http://www.anacor.com ].